Media stories about Cytori Therapeutics (NASDAQ:CYTX) have been trending somewhat positive recently, according to Accern Sentiment Analysis. Accern scores the sentiment of media coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Cytori Therapeutics earned a coverage optimism score of 0.05 on Accern’s scale. Accern also assigned press coverage about the biotechnology company an impact score of 47.1846849656437 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

Several equities research analysts have commented on the stock. ValuEngine raised shares of Cytori Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, June 2nd. HC Wainwright set a $40.00 price target on shares of Cytori Therapeutics and gave the company a “buy” rating in a report on Monday, May 14th. Maxim Group set a $20.00 price target on shares of Cytori Therapeutics and gave the company a “buy” rating in a report on Friday, May 11th. Finally, Zacks Investment Research raised shares of Cytori Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, July 11th. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $10.56.

NASDAQ:CYTX remained flat at $$0.52 during mid-day trading on Tuesday. 471,600 shares of the company’s stock traded hands, compared to its average volume of 290,195. Cytori Therapeutics has a one year low of $0.31 and a one year high of $8.70. The stock has a market capitalization of $4.02 million, a price-to-earnings ratio of -0.08 and a beta of 2.56.

Cytori Therapeutics (NASDAQ:CYTX) last posted its quarterly earnings results on Tuesday, August 14th. The biotechnology company reported ($0.59) EPS for the quarter, missing the consensus estimate of ($0.50) by ($0.09). Cytori Therapeutics had a negative net margin of 380.64% and a negative return on equity of 202.09%. The business had revenue of $1.56 million during the quarter, compared to analysts’ expectations of $2.50 million. equities research analysts anticipate that Cytori Therapeutics will post -0.85 EPS for the current fiscal year.

Cytori Therapeutics Company Profile

Cytori Therapeutics, Inc, a therapeutics company, together with its subsidiaries, develops regenerative and oncologic therapies from its proprietary cell therapy and nanoparticle platforms for various medical conditions. Its lead drug candidate, ATI-0918, is a generic version of pegylated liposomal encapsulated doxorubicin, which is in Phase III clinical trial and used for various cancer types.

See Also: Stock Symbol

Insider Buying and Selling by Quarter for Cytori Therapeutics (NASDAQ:CYTX)

Receive News & Ratings for Cytori Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytori Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.